Curr Health Sci J, vol. 45, no. 2, 2019

Colorectal Cancer: An Update on Treatment Options and Future Perspectives

[Review]

R.M. FLORESCU-TENEA(1), A.M. KAMAL(2), P. MITRUT(3,4), R. MITRUT(1), D.S. ILIE(1), A.C. NICOLAESCU(5), L. MOGOANTA(6)


(1)PhD Student, Department of Histology, University of Medicine and Pharmacy of Craiova, Romania,
(2)Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Gastroenterology, “Renaşterea” Medical Center, Craiova, Romania,
(4)Department of Semiology, University of Medicine and Pharmacy of Craiova, Romania,
(5)PhD Student, Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania,
(6)Department of Histology, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

Throughout the years, colorectal cancer has steadily become a global health problem. While other types of cancers have seen a decline in cases because of screening and vaccination programs, colorectal cancer has risen become the third most diagnosed cancer worldwide and, more worryingly, the second leading cancer-related cause of death. The introduction of targeted therapy has been widely considered a major paradigm shift in the treatment of colorectal cancer, which agents such as bevacizumab and cetuximab quickly becoming mainstay options in the treatment of locally advanced or metastatic disease. However, this type of treatment has also shown its limitations, with limited or no benefit for a large portion of the patients. With more and more knowledge being gathered on the molecular mechanisms which govern the malignant phenotype presented by colorectal cancer, scientists are engaged in a continuous effort to develop new therapies based on these discoveries.


Keywords:
Colorectal cancer, biomarkers, checkpoint inhibitors, immunohistochemistry



Corresponding:
Adina Maria Kamal, Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Dolj County, Romania, e-mail: adinaka@gmail.com


DOI 10.12865/CHSJ.45.02.02 - Download PDF